On 29 October, Terumo Interventional Systems announced the launch of the 0.018” Glidewire Advantage peripheral guidewire during the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, USA (27 October–1 November).
The new 0.018” wire reduces the need for multiple wire exchanges, a press release from the company says.
The guidewire is intended to be a first-choice guidewire enabling physicians to confidently cross the lesion, deliver the interventional device, and maintain access throughout the procedure using a single wire. With the addition of a new size, the Glidewire Advantage line of specialty guidewires can now be used in a broader range of procedures including visceral, above-the-knee and below-the-knee applications.
Terumo employs its proprietary Duocore technology that fuses the original hydrophilic-coated Glidewire guidewire construction with a stiffer nitinol core encapsulated by a spiral, polytetrafluoroethylene coating. This unique design eliminates the need for multiple wire exchanges, which may reduce the risk of patient complications.
“With the US hydrophilic guidewire market growing steadily, this is the right time to broaden our product portfolio. We continue to innovate and expand our market-leading Glidewire guidewire franchise to allow physicians to extend further into the vasculature to treat a wider variety of patients,” said Chris Pearson, vice president, Marketing, Terumo Interventional Systems. “In combination with our comprehensive training and education programs, we are bringing value to our customers who are performing life‰Ûsaving procedures.”
